Literature DB >> 17391657

Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor.

Inmaculada C Villar1, Catherine M Panayiotou, Adil Sheraz, Melanie Madhani, Ramona S Scotland, Muriel Nobles, Barbara Kemp-Harper, Amrita Ahluwalia, Adrian J Hobbs.   

Abstract

OBJECTIVE: C-type natriuretic peptide (CNP) has recently been suggested to represent an endothelium-derived hyperpolarising factor (EDHF) in the mammalian resistance vasculature and, as such, important in the regulation of local blood flow and systemic blood pressure. Additionally, this peptide has been shown to protect against ischaemia-reperfusion injury and inhibits leukocyte and platelet activation. Herein, we use a novel, selective natriuretic peptide receptor-C (NPR-C) antagonist (M372049) to highlight the pivotal contribution of CNP/NPR-C signalling in the EDHF-dependent regulation of vascular tone and investigate the mechanism(s) underlying the release and biological activity of CNP.
METHODS: In vitro pharmacological investigation was conducted in rat (Sprague-Dawley) aorta and mesenteric resistance arteries. Relaxant responses to CNP, atrial natriuretic peptide (ANP), the nitric oxide donor spermine-NONOate (SPER-NO) and the endothelium-dependent vasodilator, acetylcholine (ACh) were examined in the absence and presence of M372049 or inhibitor cocktails shown previously to block endothelium-dependent dilatation in the resistance vasculature. RT-PCR was employed to characterize the expression of NPR subtypes in the vessels studied.
RESULTS: M372049 produced concentration-dependent inhibition of the vasorelaxant activity of CNP in rat isolated mesenteric resistance arteries but not aorta; in contrast, M372049 did not affect relaxations to ANP or SPER-NO in either vessel. M372049 or ouabain alone produced small, significant inhibition of EDHF-dependent relaxations in mesenteric arteries and in combination acted synergistically to abolish such responses. A combination of M372049 with established inhibitors of EDHF-dependent relaxation revealed that multiple, distinct pathways coordinate the bioactivity of EDHF in the resistance vasculature, and that CNP/NPR-C signalling represents a major component.
CONCLUSIONS: These data substantiate CNP/NPR-C signalling as a fundamental pathway underlying EDHF-dependent regulation of vascular tone in the rat mesenteric resistance vasculature. An increased understanding of the physiological roles of CNP/NPR-C signalling in the vasculature (now facilitated by the identification of a selective NPR-C antagonist) should aid determination of the (patho)physiological importance of EDHF and might provide the rationale for the design of novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391657      PMCID: PMC3503309          DOI: 10.1016/j.cardiores.2007.02.032

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  45 in total

1.  Endothelium-dependent hyperpolarization as a remote anti-atherogenic mechanism.

Authors:  Stavros Selemidis; Thomas M Cocks
Journal:  Trends Pharmacol Sci       Date:  2002-05       Impact factor: 14.819

2.  The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1.

Authors:  C A Veale; V C Alford; D Aharony; D L Banville; R A Bialecki; F J Brown; J R Damewood; C L Dantzman; P D Edwards; R T Jacobs; R C Mauger; M M Murphy; W Palmer; K K Pine; W L Rumsey; L E Garcia-Davenport; A Shaw; G B Steelman; J M Surian; E P Vacek
Journal:  Bioorg Med Chem Lett       Date:  2000-09-04       Impact factor: 2.823

Review 3.  EDHF: bringing the concepts together.

Authors:  Rudi Busse; Gillian Edwards; Michel Félétou; Ingrid Fleming; Paul M Vanhoutte; Arthur H Weston
Journal:  Trends Pharmacol Sci       Date:  2002-08       Impact factor: 14.819

4.  Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression.

Authors:  Linda Connelly; Aaron T Jacobs; Miriam Palacios-Callender; Salvador Moncada; Adrian J Hobbs
Journal:  J Biol Chem       Date:  2003-05-09       Impact factor: 5.157

5.  Characterization of the endothelium-derived hyperpolarizing factor (EDHF) response in the human interlobar artery.

Authors:  Eckhart Büssemaker; Rüdiger Popp; Jochen Binder; Rudi Busse; Ingrid Fleming
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

6.  Depletion of natriuretic peptide C receptors eliminates inhibitory effects of C-type natriuretic peptide on evoked neurotransmitter efflux.

Authors:  G J Trachte
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

7.  Comparison of the pharmacological properties of EDHF-mediated vasorelaxation in guinea-pig cerebral and mesenteric resistance vessels.

Authors:  H Dong; Y Jiang; W C Cole; C R Triggle
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Characterization of an apamin-sensitive small-conductance Ca(2+)-activated K(+) channel in porcine coronary artery endothelium: relevance to EDHF.

Authors:  M P Burnham; R Bychkov; M Félétou; G R Richards; P M Vanhoutte; A H Weston; G Edwards
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

9.  Selective blockade of endothelial Ca2+-activated small- and intermediate-conductance K+-channels suppresses EDHF-mediated vasodilation.

Authors:  Ines Eichler; Judith Wibawa; Ivica Grgic; Andrea Knorr; Susanne Brakemeier; Axel R Pries; Joachim Hoyer; Ralf Köhler
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

10.  Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor.

Authors:  Sharmila D Chauhan; Holger Nilsson; Amrita Ahluwalia; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more
  34 in total

Review 1.  Natriuretic peptide C receptor signalling in the heart and vasculature.

Authors:  Robert A Rose; Wayne R Giles
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

Review 2.  Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.

Authors:  Matthias Barton; Oliver Baretella; Matthias R Meyer
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Localization profiles of natriuretic peptides in hearts of pre-hibernating and hibernating Anatolian ground squirrels (Spermophilus xanthoprymnus).

Authors:  Mustafa Öztop; Mehmet Özbek; Narin Liman; Feyzullah Beyaz; Emel Ergün; Levent Ergün
Journal:  Vet Res Commun       Date:  2019-01-28       Impact factor: 2.459

Review 4.  Endothelium-derived hyperpolarising factors and associated pathways: a synopsis.

Authors:  Gillian Edwards; Michel Félétou; Arthur H Weston
Journal:  Pflugers Arch       Date:  2010-04-11       Impact factor: 3.657

5.  Exogenous C-type natriuretic peptide infusion ameliorates unilateral ureteral obstruction-induced tubulointerstitial fibrosis in rats.

Authors:  Peng Hu; Xiao Cen Zhang; Hai Bo Kong; Xun Xia; Bo Hu; Yuan Han Qin
Journal:  Lab Invest       Date:  2014-12-01       Impact factor: 5.662

Review 6.  NPR-C: a component of the natriuretic peptide family with implications in human diseases.

Authors:  Speranza Rubattu; Sebastiano Sciarretta; Angelica Morriello; Camilla Calvieri; Allegra Battistoni; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2010-06-19       Impact factor: 4.599

7.  Functional pharmacological characterization of SER100 in cardiovascular health and disease.

Authors:  Inmaculada C Villar; Kristen J Bubb; Amie J Moyes; Eva Steiness; Trygve Gulbrandsen; Finn Olav Levy; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

Review 8.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

9.  Modified Synthesis of the Peptidomimetic Natriuretic Peptide Receptor-C Antagonist M372049.

Authors:  Jacob D Porter; Sergey V Lindeman; Chris Dockendorff
Journal:  Tetrahedron Lett       Date:  2020-01-22       Impact factor: 2.415

10.  Evidence against C-type natriuretic peptide as an arterial 'EDHF'.

Authors:  C J Garland; K A Dora
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.